` MDXH (MDxHealth SA) vs S&P 500 Comparison - Alpha Spread

M
MDXH
vs
S&P 500

Over the past 12 months, MDXH has significantly outperformed S&P 500, delivering a return of +40% compared to the S&P 500's +15% growth.

Stocks Performance
MDXH vs S&P 500

Loading
MDXH
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
MDXH vs S&P 500

Loading
MDXH
S&P 500
Difference
www.alphaspread.com

Performance By Year
MDXH vs S&P 500

Loading
MDXH
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
MDxHealth SA vs Peers

S&P 500
MDXH
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

MDxHealth SA
Glance View

Market Cap
156.9m USD
Industry
Biotechnology

MDxHealth SA engages in the development and commercialization of molecular diagnostic products for personalized cancer treatment. The company is headquartered in Herstal, Liege. The company went IPO on 2006-06-26. The Company’s tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, as well as prediction of response to a specific therapy. Its tests include ConfirmMDx for Prostate Cancer, SelectMDx for Prostate Cancer, PredictMDx for Glioblastoma and AssureMDx for Bladder Cancer. The firm's corporate operations are based in Herstal, Belgium, as well as Irvine, the United States, and its laboratory operations are based in Nijmegen, the Netherlands, as well as Irvine, the United States.

MDXH Intrinsic Value
4.86 USD
Undervaluation 35%
Intrinsic Value
Price
M
Back to Top